In DLBCL, where BCL6 serves as a therapeutic target (8), 77 regulators of the major module underwent a reduction in expression in a manner similar to BCL6; meanwhile, 18 regulators of the other module exhibited the opposite expression pattern (Figure 6D). This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.